- Home
- YCBD vs CERO Comparison
YCBD vs CERO Comparison
Compare YCBD & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YCBD
- CERO
- Stock Information
- Founded
- YCBD 2015
- CERO 2017
- Country
- YCBD United States
- CERO United States
- Employees
- YCBD N/A
- CERO N/A
- Industry
- YCBD Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- YCBD Health Care
- CERO
- Exchange
- YCBD Nasdaq
- CERO Nasdaq
- Market Cap
- YCBD 3.2M
- CERO 3.1M
- IPO Year
- YCBD N/A
- CERO N/A
- Fundamental
- Price
- YCBD $0.30
- CERO $0.73
- Analyst Decision
- YCBD
- CERO
- Analyst Count
- YCBD 0
- CERO 0
- Target Price
- YCBD N/A
- CERO N/A
- AVG Volume (30 Days)
- YCBD 965.3K
- CERO 1.0M
- Earning Date
- YCBD 05-14-2025
- CERO 05-16-2025
- Dividend Yield
- YCBD N/A
- CERO N/A
- EPS Growth
- YCBD N/A
- CERO N/A
- EPS
- YCBD N/A
- CERO N/A
- Revenue
- YCBD $19,220,238.00
- CERO N/A
- Revenue This Year
- YCBD $13.00
- CERO N/A
- Revenue Next Year
- YCBD $10.00
- CERO N/A
- P/E Ratio
- YCBD N/A
- CERO N/A
- Revenue Growth
- YCBD N/A
- CERO N/A
- 52 Week Low
- YCBD $0.21
- CERO $0.65
- 52 Week High
- YCBD $1.25
- CERO $223.00
- Technical
- Relative Strength Index (RSI)
- YCBD 47.12
- CERO 26.02
- Support Level
- YCBD $0.21
- CERO $0.65
- Resistance Level
- YCBD $0.42
- CERO $0.80
- Average True Range (ATR)
- YCBD 0.04
- CERO 0.10
- MACD
- YCBD 0.01
- CERO 0.04
- Stochastic Oscillator
- YCBD 44.43
- CERO 20.79
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.